Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing

Cue Biopharma, Inc.

1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.
Common stock begins trading post-split on April 24 under symbol CUE; new CUSIP 22978P205.
Reverse split aims to meet Nasdaq minimum bid price requirement, as disclosed in proxy statement.
No change in authorized shares ($0.001 par); options and warrants proportionately adjusted.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cue Biopharma, Inc.: 1-for-30 reverse stock split effected by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2026-04-23).

Change: charter amendment
Effective: 2026-04-23

Exact text from the filing

On April 22, 2026, Cue Biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on April 23, 2026 (the “Effective Time”), a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-168907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.